These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9761116)

  • 1. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
    Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
    Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
    Khyatti M; Stefanescu I; Blagdon M; Menezes J
    J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
    Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
    Shimakage M; Dezawa T; Chatani M
    Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
    Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
    J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to LMP2A/2B in EBV-carrying malignancies.
    Lennette ET; Winberg G; Yadav M; Enblad G; Klein G
    Eur J Cancer; 1995 Oct; 31A(11):1875-8. PubMed ID: 8541116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
    Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
    J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.
    Ho HC; Ng MH; Kwan HC; Chau JC
    Br J Cancer; 1976 Dec; 34(6):655-60. PubMed ID: 188437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 13. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk.
    Coghill AE; Bu W; Hsu WL; Nguyen H; Yu KJ; Chien YC; Chen CJ; Cohen JI; Hildesheim A
    J Infect Dis; 2018 Aug; 218(6):886-891. PubMed ID: 29718378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An enzyme-linked immunosorbent assay for the measurement of human IgA antibody responses to Epstein-Barr virus membrane antigen.
    Durda PJ; Sullivan M; Kieff E; Pearson GR; Rabin H
    Intervirology; 1993; 36(1):11-9. PubMed ID: 8225907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low-avidity IgG against Epstein-Barr virus capsid antigen in children.
    Votava M; Bartosová D; Krchnáková A; Crhová K; Kubinová L
    Acta Virol; 1996 Apr; 40(2):99-101. PubMed ID: 8886119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology.
    Gu AD; Xie YB; Mo HY; Jia WH; Li MY; Li M; Chen LZ; Feng QS; Liu Q; Qian CN; Zeng YX
    J Gen Virol; 2008 May; 89(Pt 5):1152-1158. PubMed ID: 18420792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune response in Epstein-Barr virus infections. I. Elevated serum concentration of the IgG1 subclass in infectious mononucleosis and nasopharyngeal carcinoma.
    Kaschka WP; Hilgers R; Skvaril F
    Clin Exp Immunol; 1982 Jul; 49(1):149-56. PubMed ID: 6290114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
    Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
    J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.